Sales in the first six months of 1996 at Sandoz amounted to 7.9 billion Swiss francs ($6.2 billion). Excluding divestitures, the group said this represented an increase of 8% in local currencies and 7% in Swiss franc terms.
The acceleration in the speed of growth was attributed to an "outstanding performance" by the pharmaceuticals division. Prescription product sales advanced 12%, due to sustained expansion of the biggest-selling drugs, the company said.
The breakdown of turnover for the first six months of the year (in million Swiss francs) is as follows:
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze